Cargando…
Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
We conducted an age-based risk analysis of meningococcal disease in Spain to provide prospects on a rational vaccine schedule in pediatrics. We used the National Hospital Registry to estimate meningococcal hospitalization rate. Population census for each year was used as the denominator in computing...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026321/ https://www.ncbi.nlm.nih.gov/pubmed/35455341 http://dx.doi.org/10.3390/vaccines10040592 |
_version_ | 1784691094981705728 |
---|---|
author | Rivero-Calle, Irene Raguindin, Peter Francis Pardo-Seco, Jacobo Martinon-Torres, Federico |
author_facet | Rivero-Calle, Irene Raguindin, Peter Francis Pardo-Seco, Jacobo Martinon-Torres, Federico |
author_sort | Rivero-Calle, Irene |
collection | PubMed |
description | We conducted an age-based risk analysis of meningococcal disease in Spain to provide prospects on a rational vaccine schedule in pediatrics. We used the National Hospital Registry to estimate meningococcal hospitalization rate. Population census for each year was used as the denominator in computing the hospitalization rate. We computed the odds ratio of each age using <1 year old as a reference group. From 1998 to 2017, 13,554 hospitalized cases were diagnosed, with a declining trend across the years. Infants (<1 year, n = 2425) and children (1–14 years, n = 6053) comprised the majority of all hospitalized meningococcal disease in Spain (62.5% or 8474/13,554). The incidence of hospitalization decreased dramatically with age from 56.2/100,000 in <1-year-old children to 1.3/100,000 in >5-year-old children. There was a dramatic decline in risk in 1 year (OR 0.58) to 4 years of age (OR 0.21). The risk continued to decline until 13 years old. Afterward, it had a minimal upward trajectory observed at 14–17 years old (OR 0.08). Infants and adolescents are at continued risk of invasive meningococcal disease in Spain. The highest risk occurs in infants. Surveillance data, together with evidence on long-term immunogenicity and capacity for herd effect, should be considered for a more relevant immunization schedule. |
format | Online Article Text |
id | pubmed-9026321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90263212022-04-23 Risk Analysis by Age on the Burden of Meningococcal Disease in Spain Rivero-Calle, Irene Raguindin, Peter Francis Pardo-Seco, Jacobo Martinon-Torres, Federico Vaccines (Basel) Article We conducted an age-based risk analysis of meningococcal disease in Spain to provide prospects on a rational vaccine schedule in pediatrics. We used the National Hospital Registry to estimate meningococcal hospitalization rate. Population census for each year was used as the denominator in computing the hospitalization rate. We computed the odds ratio of each age using <1 year old as a reference group. From 1998 to 2017, 13,554 hospitalized cases were diagnosed, with a declining trend across the years. Infants (<1 year, n = 2425) and children (1–14 years, n = 6053) comprised the majority of all hospitalized meningococcal disease in Spain (62.5% or 8474/13,554). The incidence of hospitalization decreased dramatically with age from 56.2/100,000 in <1-year-old children to 1.3/100,000 in >5-year-old children. There was a dramatic decline in risk in 1 year (OR 0.58) to 4 years of age (OR 0.21). The risk continued to decline until 13 years old. Afterward, it had a minimal upward trajectory observed at 14–17 years old (OR 0.08). Infants and adolescents are at continued risk of invasive meningococcal disease in Spain. The highest risk occurs in infants. Surveillance data, together with evidence on long-term immunogenicity and capacity for herd effect, should be considered for a more relevant immunization schedule. MDPI 2022-04-12 /pmc/articles/PMC9026321/ /pubmed/35455341 http://dx.doi.org/10.3390/vaccines10040592 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rivero-Calle, Irene Raguindin, Peter Francis Pardo-Seco, Jacobo Martinon-Torres, Federico Risk Analysis by Age on the Burden of Meningococcal Disease in Spain |
title | Risk Analysis by Age on the Burden of Meningococcal Disease in Spain |
title_full | Risk Analysis by Age on the Burden of Meningococcal Disease in Spain |
title_fullStr | Risk Analysis by Age on the Burden of Meningococcal Disease in Spain |
title_full_unstemmed | Risk Analysis by Age on the Burden of Meningococcal Disease in Spain |
title_short | Risk Analysis by Age on the Burden of Meningococcal Disease in Spain |
title_sort | risk analysis by age on the burden of meningococcal disease in spain |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026321/ https://www.ncbi.nlm.nih.gov/pubmed/35455341 http://dx.doi.org/10.3390/vaccines10040592 |
work_keys_str_mv | AT riverocalleirene riskanalysisbyageontheburdenofmeningococcaldiseaseinspain AT raguindinpeterfrancis riskanalysisbyageontheburdenofmeningococcaldiseaseinspain AT pardosecojacobo riskanalysisbyageontheburdenofmeningococcaldiseaseinspain AT martinontorresfederico riskanalysisbyageontheburdenofmeningococcaldiseaseinspain |